No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 11,910 | 12,869 | 14,529 | 13,184 | 15,534 | 17,231 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 1,352 | 1,472 | 1,247 | 52 | 1,204 | 1,155 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Bluestar Adisseo Company operates as a global leader in the development, production, and distribution of specialized feed additives for animal nutrition. The company's diverse product portfolio includes Rhodimet, a range of methionine-based solutions for monogastric animals, offered in both solid (Rhodimet NP99) and liquid (Rhodimet AT88) forms. Additionally, it provides advanced nutritional formulas, such as Smartamine and MetaSmart, which are engineered to ensure optimal amino acid balance in the diets of lactating dairy cows and other ruminants. Its Microvit range offers a comprehensive selection of vitamins essential for the feed industry. Adisseo also produces a diverse array of enzyme preparations under the Rovabio brand, formulated to enhance the digestibility of plant-based raw materials for various animal species, including poultry and swine. Another significant offering is Selisseo 2% Se, an organic selenium source based on seleno-hydroxy-methionine, designed for integration into animal feed. The firm supplies AdiSodium, a chloride-free sodium alternative that supports dietary electrolyte balance in monogastric feeds and delivers an assimilable form of sulfur to ruminant diets. Furthermore, Alterion is provided to improve animal gut health and overall performance by fostering a balanced intestinal micro-ecosystem. Complementing its product portfolio, the company provides several specialized services. PNE utilizes Near-Infrared (NIR) technology to accurately predict the nutritional quality of feed raw materials. DiM offers dedicated assistance and application support for its Rhodimet AT88 product. Lastly, E-lab is an online portal facilitating analytical requests and simplifying sample identification for customers prior to shipment to Adisseo's laboratories. Founded in 1939 and headquartered in Beijing, China, Bluestar Adisseo Company functions as a subsidiary of China National Bluestar (Group) Co., Ltd.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Bluestar Adisseo Company (600299.SS)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Bluestar Adisseo Company operates as a global leader in the development, production, and distribution of specialized feed additives for animal nutrition. The company's diverse product portfolio includes Rhodimet, a range of methionine-based solutions for monogastric animals, offered in both solid (Rhodimet NP99) and liquid (Rhodimet AT88) forms. Additionally, it provides advanced nutritional formulas, such as Smartamine and MetaSmart, which are engineered to ensure optimal amino acid balance in the diets of lactating dairy cows and other ruminants. Its Microvit range offers a comprehensive selection of vitamins essential for the feed industry. Adisseo also produces a diverse array of enzyme preparations under the Rovabio brand, formulated to enhance the digestibility of plant-based raw materials for various animal species, including poultry and swine. Another significant offering is Selisseo 2% Se, an organic selenium source based on seleno-hydroxy-methionine, designed for integration into animal feed. The firm supplies AdiSodium, a chloride-free sodium alternative that supports dietary electrolyte balance in monogastric feeds and delivers an assimilable form of sulfur to ruminant diets. Furthermore, Alterion is provided to improve animal gut health and overall performance by fostering a balanced intestinal micro-ecosystem. Complementing its product portfolio, the company provides several specialized services. PNE utilizes Near-Infrared (NIR) technology to accurately predict the nutritional quality of feed raw materials. DiM offers dedicated assistance and application support for its Rhodimet AT88 product. Lastly, E-lab is an online portal facilitating analytical requests and simplifying sample identification for customers prior to shipment to Adisseo's laboratories. Founded in 1939 and headquartered in Beijing, China, Bluestar Adisseo Company functions as a subsidiary of China National Bluestar (Group) Co., Ltd.